Itolizumab [bmab 600] (DrugBank: Itolizumab)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
49 | Systemic lupus erythematosus | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04128579 (ClinicalTrials.gov) | October 1, 2019 | 30/9/2019 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | A Phase 1b Multiple Ascending-dose Study of EQ001 in Subjects With Systemic Lupus Erythematosus With or Without Active Proliferative Lupus Nephritis | Lupus Erythematosus;Lupus Nephritis | Drug: Itolizumab [Bmab 600] | Equillium | Biocon Limited | Recruiting | 18 Years | 75 Years | All | 60 | Phase 1 | United States |